eMedicine Specialties > Infectious Diseases > Skin and Soft-Tissue Infections

Mycetoma

Author: Basilio J Anía, MD, Consultant in Internal Medicine, Associate Professor of Infectious Diseases, Department of Internal Medicine, Division of Infectious Diseases, Hospital Negrín & Universidad de Las Palmas de Gran Canaria, Spain
Coauthor(s): Margarita Asenjo, MD, Associate Professor, Department of Radiology, Medical School of the University of Las Palmas De Gran Canaria, Spain; Raphael J Kiel, MD, Associate Professor of Medicine, Wayne State University School of Medicine; Associate Program Director, Head of Infectious Disease Section, Department of Internal Medicine, Oakwood Hospital
Contributor Information and Disclosures

Updated: Aug 30, 2008

Introduction

Background

Mycetoma is a chronic subcutaneous infection caused by actinomycetes or fungi. This infection results in a granulomatous inflammatory response in the deep dermis and subcutaneous tissue, which can extend to the underlying bone. Mycetoma is characterized by the formation of grains containing aggregates of the causative organisms that may be discharged onto the skin surface through multiple sinuses. Mycetoma was first described in the mid 1800s and initially named Madura foot, after the region of Madura in India where the disease was first identified.

Mycetoma caused by microaerophilic actinomycetes is termed actinomycetoma, and mycetoma caused by true fungi is called eumycetoma. These conditions are to be differentiated from actinomycosis, which is an endogenous suppurative infection caused by Actinomyces israelii or other species of Actinomyces or related bacteria, affecting the cervical-facial, thoracic, and pelvic sites (the latter is usually associated with the use of intrauterine devices). The branching bacteria that cause actinomycosis are non–acid-fast anaerobic or microaerophilic bacteria. These bacteria are smaller than 1 µm in diameter, smaller than eumycotic agents. On the other hand, the agents that cause actinomycetoma are always aerobic and are sometimes weakly acid-fast.

More than 20 species of fungi and bacteria can cause mycetoma. The ratio of mycetoma cases caused by bacteria (actinomycetoma) to those caused by true fungi (eumycetoma) is 197:67.

Pathophysiology

The body parts affected most commonly in persons with mycetoma include the foot or lower leg, with infection of the dorsal aspect of the forefoot being typical. The hand is the next most common location; however, mycetoma lesions can occur anywhere on the body. Lesions on the chest and back are frequently caused by Nocardia species, whereas lesions on the head and neck are usually caused by Streptomyces somaliensis.

The causative organism enters through sites of local trauma (eg, cut on the hand, foot splinter, local trauma related to carrying soil-contaminated material). A neutrophilic response initially occurs, which may be followed by a granulomatous reaction. Spread occurs through skin facial planes and can involve the bone. Hematogenous or lymphatic spread is uncommon.

Frequency

United States

Mycetoma is rare in the United States. Some cases are due to increasing international travel. Rarely, mycetoma is acquired on US soil.1 Pseudallescheria boydii (Scedosporium apiospermum) is the most common cause of this condition.

International

Mycetoma is endemic in Africa, from Sudan and Somalia through Mauritania and Senegal. Other endemic countries include Mexico and India; however, mycetoma can also be found in natives of areas of Central and South America and the Middle or Far East between latitudes 15°S and 30°N. In Sudanese hospitals, at least 300-400 patients are diagnosed with mycetoma every year.

Mortality/Morbidity

Mycetoma causes disfigurement but is rarely fatal in the absence of skull involvement. The lesions are painless and slowly progressive; however, secondary bacterial infection or bone expansion may cause pain. In advanced cases, deformities or ankylosis and their corresponding disabilities can appear. Patients who are immunocompromised or who have undergone transplantation can develop invasive infection.

Race

Mycetoma has no apparent racial predilection.

Sex

Mycetoma has a male-to-female ratio of 183:81.

Age

Mycetoma is most common in persons aged 20-50 years.

Clinical

History

  • The earliest sign of mycetoma is a painless subcutaneous swelling. Some patients have a history of a penetrating injury at that site.
  • Several years later, a painless subcutaneous nodule is observed. After some years, massive swelling of the area occurs, with induration, skin rupture, and sinus tract formation.
  • As the infection spreads to contiguous body parts, old sinuses close and new ones open.
  • Nearly 20% of patients with mycetoma experience associated pain, usually due to secondary bacterial infection or, less commonly, bone invasion.
  • Constitutional symptoms and signs of mycetoma are rare.
  • Patients may report a deep itching sensation.

Physical

  • Irrespective of the causal agent, the appearance of the mycetoma lesion is consistent, as follows:
    • Initially, subcutaneous swelling is present.
    • In a later phase, a subcutaneous nodule develops.
    • Eventually, massive swelling with induration, rupture of the skin, and formation of sinus tracts occur.
  • In general, eumycetoma is more circumscribed and progresses slower than actinomycetoma.
  • Regional lymphadenopathy is unusual; when it does occur, it is due to one of the following:
    • Lymphatic spread of mycetoma to regional nodes occurs in only 1-3% of affected patients.
    • Secondary bacterial infection or a local immunologic reaction may enlarge the regional lymph nodes.
  • Lymphatic obstruction and fibrosis can cause lymphedema and erythema.
  • Pulmonary mycetoma has been found to develop and progress more rapidly in individuals infected with HIV.

Causes

  • Mycetoma occurs most often in farmers, shepherds, Bedouins, nomads, and people living in rural areas.
  • Frequent exposure to penetrating wounds by thorns or splinters is a risk factor.
  • Actinomycetoma can be caused by the following:
    • Actinomadura madurae
    • Actinomadura pelletieri
    • S somaliensis
    • Nocardia species
  • Eumycetoma is caused primarily by P boydii (S apiospermum).

More on Mycetoma

Overview: Mycetoma
Differential Diagnoses & Workup: Mycetoma
Treatment & Medication: Mycetoma
Follow-up: Mycetoma
Multimedia: Mycetoma
References
[ CLOSE WINDOW ]

References

  1. Rouphael NG, Talati NJ, Franco-Paredes C. A painful thorn in the foot: a case of eumycetoma. Am J Med Sci. Aug 2007;334(2):142-4. [Medline].

  2. Kumar J, Kumar A, Sethy P, et al. The dot-in-circle sign of mycetoma on MRI. Diagn Interv Radiol. Dec 2007;13(4):193-5. [Medline]. [Full Text].

  3. Ahmed AA, van de Sande WW, Fahal A, et al. Management of mycetoma: major challenge in tropical mycoses with limited international recognition. Curr Opin Infect Dis. Apr 2007;20(2):146-51. [Medline].

  4. Falkson C, Sur R, Pacella J. External beam radiotherapy: a treatment option for massive haemoptysis caused by mycetoma. Clin Oncol (R Coll Radiol). Jun 2002;14(3):233-5. [Medline].

  5. Baril L, Boiron P, Manceron V, et al. Refractory craniofacial actinomycetoma due to Streptomyces somaliensis that required salvage therapy with amikacin and imipenem. Clin Infect Dis. Aug 1999;29(2):460-1. [Medline].

  6. Ramam M, Bhat R, Garg T, et al. A modified two-step treatment for actinomycetoma. Indian J Dermatol Venereol Leprol. Jul-Aug 2007;73(4):235-9. [Medline].

  7. Abd El Bagi ME. New radiographic classification of bone involvement in pedal mycetoma. AJR Am J Roentgenol. Mar 2003;180(3):665-8. [Medline].

  8. Ahmed AO, van Leeuwen W, Fahal A, et al. Mycetoma caused by Madurella mycetomatis: a neglected infectious burden. Lancet Infect Dis. Sep 2004;4(9):566-74. [Medline].

  9. Akhtar MA, Latief PA. Actinomycetoma pedis. Postgrad Med J. Nov 1999;75(889):671. [Medline].

  10. Bapat KC, Pandit AA. Actinomycotic mycetoma. Report of a case with diagnosis by fine needle aspiration. Acta Cytol. Nov-Dec 1991;35(6):770-2. [Medline].

  11. Boiron P, Locci R, Goodfellow M, et al. Nocardia, nocardiosis and mycetoma. Med Mycol. 1998;36 Suppl 1:26-37. [Medline].

  12. Bouza E, Munoz P. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect. Mar 2004;10 Suppl 1:76-85. [Medline].

  13. Campagnaro EL, Woodside KJ, Early MG, et al. Disseminated Pseudallescheria boydii (Scedosporium apiospermum) infection in a renal transplant patient. Transpl Infect Dis. Dec 2002;4(4):207-11. [Medline].

  14. Chaveiro MA, Vieira R, Cardoso J, et al. Cutaneous infection due to Scedosporium apiospermum in an immunosuppressed patient. J Eur Acad Dermatol Venereol. Jan 2003;17(1):47-9. [Medline].

  15. Chávez G, Estrada R, Bonifaz A. Perianal actinomycetoma experience of 20 cases. Int J Dermatol. Aug 2002;41(8):491-3. [Medline].

  16. Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs. Apr 1998;55(4):585-612. [Medline].

  17. Develoux M, Dieng MT, Kane A, et al. [Management of mycetoma in West-Africa]. Bull Soc Pathol Exot. Jan 2003;96(5):376-82. [Medline].

  18. Dieng MT, Sy MH, Diop BM, et al. [Mycetoma: 130 cases]. Ann Dermatol Venereol. Jan 2003;130(1 Pt 1):16-9. [Medline].

  19. EL Hag IA, Fahal AH, Gasim ET. Fine needle aspiration cytology of mycetoma. Acta Cytol. May-Jun 1996;40(3):461-4. [Medline].

  20. Fahal AH. Mycetoma: a thorn in the flesh. Trans R Soc Trop Med Hyg. Jan 2004;98(1):3-11. [Medline].

  21. Fahal AH, Hassan MA. Mycetoma. Br J Surg. Nov 1992;79(11):1138-41. [Medline].

  22. Fahal AH, Sheik HE, Homeida MM, et al. Ultrasonographic imaging of mycetoma. Br J Surg. Aug 1997;84(8):1120-2. [Medline].

  23. Fletcher CL, Moore MK, Hay RJ. Eumycetoma due to Madurella mycetomatis acquired in Jamaica. Br J Dermatol. Dec 2001;145(6):1018-21. [Medline].

  24. Greenberg AK, Knapp J, Rom WN, et al. Clinical presentation of pulmonary mycetoma in HIV-infected patients. Chest. Sep 2002;122(3):886-92. [Medline].

  25. Hay RJ. Fungal infections. In: Cook GC, ed. Manson's Tropical Diseases. 20th ed. London, UK: WB Saunders; 1996:1047-74.

  26. Hay RJ, Moore M. Mycology. In: Champion RH, Wilkinson DS, Ebling FJG, Breathnach SM, eds. Rook/Wilkinson/Ebling Textbook of Dermatology. Vol 2. 6th ed. Oxford, UK: Blackwell Science; 1998:1277-376.

  27. Khatri ML, Al-Halali HM, Fouad Khalid M, et al. Mycetoma in Yemen: clinicoepidemiologic and histopathologic study. Int J Dermatol. Sep 2002;41(9):586-93. [Medline].

  28. Lichon V, Khachemoune A. Mycetoma : a review. Am J Clin Dermatol. 2006;7(5):315-21. [Medline].

  29. Mahgoub ES. Medical management of mycetoma. Bull World Health Organ. 1976;54(3):303-10. [Medline].

  30. Mahgoub ES. Agents of mycetoma. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. Vol 2. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000:2702-6.

  31. Maiti PK, Ray A, Bandyopadhyay S. Epidemiological aspects of mycetoma from a retrospective study of 264 cases in West Bengal. Trop Med Int Health. Sep 2002;7(9):788-92. [Medline].

  32. Mellinghoff IK, Winston DJ, Mukwaya G, et al. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis. Jun 15 2002;34(12):1648-50. [Medline].

  33. Mendez-Tovar LJ, Mondragon-Gonzalez R, Manzano-Gayosso P, et al. [Immunoglobulins in patients with Nocardia brasiliensis actinomycetoma]. Rev Argent Microbiol. Oct-Dec 2004;36(4):174-8. [Medline].

  34. O'Bryan TA. Pseudallescheriasis in the 21st century. Expert Rev Anti Infect Ther. Oct 2005;3(5):765-73. [Medline].

  35. Poncio Mendes R, Negroni R, Bonifaz A, et al. New aspects of some endemic mycoses. Med Mycol. 2000;38 Suppl 1:237-41. [Medline].

  36. Queiroz-Telles F, McGinnis MR, Salkin I, et al. Subcutaneous mycoses. Infect Dis Clin North Am. Mar 2003;17(1):59-85, viii. [Medline].

  37. Ramam M, Garg T, D'Souza P, et al. A two-step schedule for the treatment of actinomycotic mycetomas. Acta Derm Venereol. Sep-Oct 2000;80(5):378-80. [Medline].

  38. Saag MS. Mycetoma. In: Goldman L, Bennett JC, eds. Cecil Textbook of Medicine. ed. Philadelphia, Pa: WB Saunders; 2000:1885-7.

  39. Saarinen KA, Lestringant GG, Czechowski J, et al. Cutaneous nocardiosis of the chest wall and pleura--10-year consequences of a hand actinomycetoma. Dermatology. 2001;202(2):131-3. [Medline].

  40. Sharma N, Mendiratta V, Sharma RC, et al. Pulse therapy with amikacin and dapsone for the treatment of actinomycotic foot: a case report. J Dermatol. Oct 2003;30(10):742-7. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

mycetoma, maduromycosis, Madura foot, actinomycetoma, eumycetoma, bacterial mycetoma, fungal mycetoma, actinomycetes, pulmonary mycetoma, mycetoma grain, Pseudallescheria boydii, P boydii, Actinomadura madurae, A madurae, Actinomadura pelletieri, A pelletieri, Streptomyces somaliensis, S somaliensis, Nocardia, Scedosporium apiospermum, S apiospermum, Streptomyces paraguayensis, S paraguayensis, Leptosphaeria, Madurella mycetomatis, M mycetomatis

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Basilio J Anía, MD, Consultant in Internal Medicine, Associate Professor of Infectious Diseases, Department of Internal Medicine, Division of Infectious Diseases, Hospital Negrín & Universidad de Las Palmas de Gran Canaria, Spain
Disclosure: Nothing to disclose.

Coauthor(s)

Margarita Asenjo, MD, Associate Professor, Department of Radiology, Medical School of the University of Las Palmas De Gran Canaria, Spain
Disclosure: Nothing to disclose.

Raphael J Kiel, MD, Associate Professor of Medicine, Wayne State University School of Medicine; Associate Program Director, Head of Infectious Disease Section, Department of Internal Medicine, Oakwood Hospital
Raphael J Kiel, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Geriatrics Society, American Medical Association, and American Medical Informatics Association
Disclosure: Nothing to disclose.

Medical Editor

Larry I Lutwick, MD, Professor of Medicine, State University of New York, Downstate Medical School; Director, Infectious Diseases, Veterans Affairs New York Harbor Health Care System, Brooklyn Campus
Larry I Lutwick, MD is a member of the following medical societies: American College of Physicians and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Michael Stuart Bronze, MD, Professor, Stewart G Wolf Chair in Internal Medicine, Department of Medicine, University of Oklahoma Health Science Center
Michael Stuart Bronze, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physician Executives, American College of Physicians, American College of Physicians-American Society of Internal Medicine, American Federation for Clinical Research, American Medical Association, American Society for Microbiology, Association of Professors of Medicine, Association of Program Directors in Internal Medicine, Infectious Diseases Society of America, Oklahoma State Medical Association, and Southern Society for Clinical Investigation
Disclosure: Nothing to disclose.

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.